1. Home
  2. MYGN vs ZVRA Comparison

MYGN vs ZVRA Comparison

Compare MYGN & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.16

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$11.21

Market Cap

472.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
ZVRA
Founded
1991
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
444.2M
472.9M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
MYGN
ZVRA
Price
$4.16
$11.21
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$7.64
$23.00
AVG Volume (30 Days)
983.9K
739.7K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
159.21
EPS
N/A
1.35
Revenue
$771,400,000.00
$106,470,000.00
Revenue This Year
$6.86
$37.27
Revenue Next Year
$5.45
$53.42
P/E Ratio
N/A
$7.90
Revenue Growth
2.33
350.91
52 Week Low
$3.76
$7.16
52 Week High
$8.59
$13.16

Technical Indicators

Market Signals
Indicator
MYGN
ZVRA
Relative Strength Index (RSI) 36.06 66.68
Support Level $3.76 $8.30
Resistance Level $5.52 $12.14
Average True Range (ATR) 0.29 0.44
MACD -0.04 0.05
Stochastic Oscillator 25.32 98.88

Price Performance

Historical Comparison
MYGN
ZVRA

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Share on Social Networks: